Octreotide shown to be of some benefit in those with stage II to IV pancreatic cancer. The number of individuals positively impacted was small (19%) for 12 weeks, but another tool in the battle against cancer.
Pegvisomant shown to provide more GH, IGF-1 suppression compared to octreotide. The doses used were 40, 60, and 80 mg SQ. The higher dose resulted in the greatest suppression.